Podcasts about oncology and hematology

  • 42PODCASTS
  • 2,169EPISODES
  • 25mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 23, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about oncology and hematology

Show all podcasts related to oncology and hematology

Latest podcast episodes about oncology and hematology

Deep Breaths: Updates from CHEST
Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges

Deep Breaths: Updates from CHEST

Play Episode Listen Later May 23, 2025


Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Deep Breaths: Updates from CHEST
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management

Deep Breaths: Updates from CHEST

Play Episode Listen Later May 23, 2025


Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Project Oncology®
First Results From Cohort 4 of the SunRISe-1 Trial

Project Oncology®

Play Episode Listen Later May 1, 2025


This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.

Project Oncology®
Trial in Progress: Phase 3 MoonRISe-3 Study

Project Oncology®

Play Episode Listen Later May 1, 2025


This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.

Conference Coverage
Recognizing and Addressing Rheumatic irAEs from Cancer Immunotherapies

Conference Coverage

Play Episode Listen Later May 1, 2025


Guest: Laura Cappelli, MD, MHS,MS Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.

Conference Coverage
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study

Conference Coverage

Play Episode Listen Later Apr 30, 2025


Guest: Ihtisham Ahmad Preclinical findings in animal models have shown that activating cannibinoid receptors can shrink prostate tumors in animal models. To explore whether these effects translate to human populations, a recent study examined a potential link between cannabis use and the development of prostate cancer. Hear from Ihtisham Ahmad, a fourth-year medical student at the University of Toronto, as he explains the methodology and findings from his research, which he presented at the American Urological Association 2025 Annual Meeting.

ReachMD CME
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma

ReachMD CME

Play Episode Listen Later Apr 15, 2025


CME credits: 0.25 Valid until: 15-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/ Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.=

Medical Industry Feature
Frontline Consolidation in B-ALL: Expert Insights on the Role of Blinatumomab

Medical Industry Feature

Play Episode Listen Later Apr 8, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Aaron Logan, MD, PhD Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each year in the US,1,2 there's been a lot of progress in the management of B-cell ALL over the years. One key development comes from the E1910 Phase III trial, which explored the addition of blinatumomab to frontline consolidation chemotherapy for patients with Philadelphia chromosome-negative B-lineage ALL (B-ALL).3 Joining Dr. Charles Turck to discuss the impacts of this data on B-ALL clinical guidelines and practice is Dr. Aaron Logan. Dr. Logan is a Professor of Clinical Medicine in the Division of Hematology/Oncology and Director of the Hematologic Malignancies Tissue Bank at UCSF. References: National Cancer Institute. SEER Cancer Stat Facts: Acute Lymphocytic Leukemia (ALL). Accessed at https://seer.cancer.gov/statfacts/html/alyl.html on March 31, 2025 Dana-Farber Cancer Institute. Acute Lymphoblastic Leukemia (ALL). Accessed September 17, 2024. https://www.dana-farber.org/cancer-care/types/acute-lymphoblastic-leukemia Litzow MR, et al. Blood. 2022;140(suppl 2):LBA-1

Project Oncology®
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies

Project Oncology®

Play Episode Listen Later Apr 7, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Medical Industry Feature
From Diagnosis to Treatment: Challenges in Glioblastoma Care

Medical Industry Feature

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Conference Coverage
From Diagnosis to Treatment: Challenges in Glioblastoma Care

Conference Coverage

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care

NeuroFrontiers

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

ReachMD CME
From Guidelines to Practice: First-Line Treatment Choices in mCRC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-guidelines-to-practice-first-line-treatment-choices-in-mcrc/32943/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

ReachMD CME
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

ReachMD CME
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

ReachMD CME
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

ReachMD CME
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

ReachMD CME
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

ReachMD CME
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

ReachMD CME
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Medical Industry Feature
Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Medical Industry Feature

Play Episode Listen Later Mar 28, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Project Oncology®
Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Project Oncology®

Play Episode Listen Later Mar 28, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

GI Insights
Screening Modalities for Colon Cancer: What You Need to Know

GI Insights

Play Episode Listen Later Mar 26, 2025


Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

ReachMD CME
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

ReachMD CME

Play Episode Listen Later Mar 26, 2025


CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.=

Project Oncology®
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

Project Oncology®

Play Episode Listen Later Mar 26, 2025


Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.

ReachMD CME
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

ReachMD CME

Play Episode Listen Later Mar 25, 2025


CME credits: 0.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/ When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! =

Medical Industry Feature
Melanoma Treatment Breakthroughs: Improving Long-Term Survival

Medical Industry Feature

Play Episode Listen Later Mar 17, 2025


Guest: Vernon K. Sondak, MD Melanoma treatment has undergone a rapid evolution. Immunotherapy has doubled survival rates, and timing the use of these drugs around surgery has shown to be even more effective. Dr. Vernon Sondak explores how the fight against melanoma is stronger than ever with new therapeutic combinations and evolving treatment strategies. Dr. Sondak is the Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

ReachMD CME
Collaborative Insights to Solve the Puzzle of Bladder Cancer

ReachMD CME

Play Episode Listen Later Mar 14, 2025


CME credits: 1.00 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-insights-to-solve-the-puzzle-of-bladder-cancer/30062/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The program also focuses on creating effective, evidence-based treatment plans and strategies for sequencing molecularly targeted therapies, as well as integrating interprofessional protocols for managing adverse events. This collaborative approach will equip learners with practical insights to enhance treatment outcomes in bladder cancer. =

Medical Industry Feature
Neoadjuvant Immunotherapy and Radiation Boosts Response in NSCLC

Medical Industry Feature

Play Episode Listen Later Mar 14, 2025


Guest: Nasser Altorki, MD Nasser Altorki, MD, chief of thoracic surgery at NewYork-Presbyterian and Weill Cornell Medicine, shares the results of a first-of-its-kind study evaluating low-dose radiation combined with immunotherapy for neoadjuvant treatment of non-small cell lung cancer (NSCLC) tumors. The dual-therapy treatment of durvalumab in combination with stereotactic body radiation was almost twice as effective at tumor killing compared to durvalumab alone. © 2025 NewYork-Presbyterian

Project Oncology®
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

Project Oncology®

Play Episode Listen Later Mar 14, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

ReachMD CME
Personalizing Care Within the RCC Treatment Paradigm

ReachMD CME

Play Episode Listen Later Mar 13, 2025


CME credits: 1.00 Valid until: 13-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-care-within-the-rcc-treatment-paradigm/29528/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Participants will gain a deeper understanding of guideline-driven treatment strategies across RCC histologies and learn strategies for the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Learners will gain actionable insights for personalizing RCC care and improving patient outcomes. =

Project Oncology®
Targeting CD123 in AML: The Latest Therapeutic Advancements

Project Oncology®

Play Episode Listen Later Mar 12, 2025


Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it's also associated with more proliferative disease that's resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In light of these new approaches, Dr. Jennifer Caudle and Dr. Naval Daver discuss the importance of targeting CD123 in AML. Dr. Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center in Houston.

Medical Industry Feature
Evaluating First-Line Therapy for Acute Graft-Versus-Host Disease

Medical Industry Feature

Play Episode Listen Later Mar 4, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response and minimize cumulative steroid exposure? Joining Dr Charles Turck to discuss the potential of nonimmunosuppressive steroid-sparing agents for the first-line treatment of aGVHD are Drs Yi Bin Chen and Olaf Penack. Dr Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital, and Dr Penack is a senior physician and principal investigator within Hematology and Oncology at Charité Berlin. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant and Cell Ther. 2022;28(10):707.e1-707.e7. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. © 2025 CSL BehringCMD-964-0016-JAN25

ReachMD CME
Differential Diagnosis of Indolent Systemic Mastocytosis

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

ReachMD CME
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

ReachMD CME
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

ReachMD CME
Is it Nonresponsive/Progressive ISM?

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

ReachMD CME
Advancing Multidisciplinary Care in TGCT: Integrating Systemic Therapies and Surgical Approaches

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.25 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-multidisciplinary-care-in-tgct-integrating-systemic-therapies-and-surgical-approaches/29871/ In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT. Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.​=

ReachMD CME
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

ReachMD CME

Play Episode Listen Later Feb 21, 2025


CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/exploring-new-and-emerging-treatments-in-muscle-invasive-bladder-cancer/32676/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

ReachMD CME
Patient Perspectives on Bladder Cancer

ReachMD CME

Play Episode Listen Later Feb 21, 2025


CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

ReachMD CME
Reviewing the Latest Bladder Cancer Practice Guidelines

ReachMD CME

Play Episode Listen Later Feb 21, 2025


CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Project Oncology®
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

Project Oncology®

Play Episode Listen Later Feb 21, 2025


Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Project Oncology®
Patient Perspectives on Bladder Cancer

Project Oncology®

Play Episode Listen Later Feb 21, 2025


Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Lillibeth Velasco, MSN, RN New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

Project Oncology®
Reviewing the Latest Bladder Cancer Practice Guidelines

Project Oncology®

Play Episode Listen Later Feb 21, 2025


Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.

ReachMD CME
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care

ReachMD CME

Play Episode Listen Later Feb 5, 2025


CME credits: 0.25 Valid until: 05-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/virtual-tumor-board-maximizing-the-potential-of-immuno-oncology-in-early-tnbc-through-personalized-care/29461/ Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of recognizing and managing immune-related adverse events (irAEs) in the perioperative setting. Learn to optimize the use of IO in early-stage TNBC and improve your patients' outcomes and quality of life. =

Medical Industry Feature
Managing the Complexities of Acute Graft-Versus-Host Disease: Current Challenges and Unmet Needs

Medical Industry Feature

Play Episode Listen Later Jan 30, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Miguel-Angel Perales, MD Guest: Anna Sureda, MD, PhD Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant Cell Ther. 2022;28(10):707.e1-707.e7. doi:10.1016/j.jtct.2022.04.014 Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic steroids. Qual Life Res. 2017;26(4):1037-1058. García-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow …

ReachMD CME
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

ReachMD CME

Play Episode Listen Later Jan 23, 2025


CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

ReachMD CME
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

ReachMD CME

Play Episode Listen Later Jan 23, 2025


CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

ReachMD CME
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

ReachMD CME

Play Episode Listen Later Jan 23, 2025


CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

GI Insights
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR

GI Insights

Play Episode Listen Later Jan 16, 2025


Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.